Business Description
![Adaptimmune Therapeutics PLC Adaptimmune Therapeutics PLC logo](https://static.gurufocus.com/logos/0C0000AW8E.png?14)
Adaptimmune Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US00653A1079
Share Class Description:
ADAP: ADRDescription
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.06 | |||||
Equity-to-Asset | 0.09 | |||||
Debt-to-Equity | 0.97 | |||||
Debt-to-EBITDA | -0.13 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -6.62 | |||||
Beneish M-Score | -2.62 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 120.5 | |||||
3-Year EBITDA Growth Rate | 10.3 | |||||
3-Year EPS without NRI Growth Rate | 11.6 | |||||
3-Year FCF Growth Rate | -22.2 | |||||
3-Year Book Growth Rate | -57.1 | |||||
Future 3-5Y Total Revenue Growth Rate | -2.75 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 64.7 | |||||
9-Day RSI | 54.03 | |||||
14-Day RSI | 48.83 | |||||
6-1 Month Momentum % | 50.7 | |||||
12-1 Month Momentum % | 14.06 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.81 | |||||
Quick Ratio | 2.81 | |||||
Cash Ratio | 2.16 | |||||
Days Sales Outstanding | 58.45 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 | |||||
Shareholder Yield % | -12.75 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1038.56 | |||||
Net Margin % | -890.13 | |||||
FCF Margin % | -753.15 | |||||
ROE % | -225.37 | |||||
ROA % | -55.64 | |||||
ROIC % | -161.46 | |||||
ROC (Joel Greenblatt) % | -262.52 | |||||
ROCE % | -85.56 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 11.58 | |||||
PB Ratio | 10.23 | |||||
Price-to-Tangible-Book | 10.8 | |||||
EV-to-EBIT | -0.67 | |||||
EV-to-EBITDA | -0.71 | |||||
EV-to-Revenue | 7 | |||||
EV-to-Forward-Revenue | 1.47 | |||||
EV-to-FCF | -0.93 | |||||
Earnings Yield (Greenblatt) % | -149.25 | |||||
FCF Yield % | -55.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ADAP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adaptimmune Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 18.358 | ||
EPS (TTM) ($) | -0.66 | ||
Beta | 2.28 | ||
Volatility % | 103.72 | ||
14-Day RSI | 48.83 | ||
14-Day ATR ($) | 0.06717 | ||
20-Day SMA ($) | 0.967545 | ||
12-1 Month Momentum % | 14.06 | ||
52-Week Range ($) | 0.42 - 2.05 | ||
Shares Outstanding (Mil) | 255.56 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Adaptimmune Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Adaptimmune Therapeutics PLC Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Adaptimmune Therapeutics PLC Frequently Asked Questions
What is Adaptimmune Therapeutics PLC(ADAP)'s stock price today?
The current price of ADAP is $0.97. The 52 week high of ADAP is $2.05 and 52 week low is $0.42.
When is next earnings date of Adaptimmune Therapeutics PLC(ADAP)?
The next earnings date of Adaptimmune Therapeutics PLC(ADAP) is 2024-08-09 Est..
Does Adaptimmune Therapeutics PLC(ADAP) pay dividends? If so, how much?
Adaptimmune Therapeutics PLC(ADAP) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |